Golidocitinib Plus CHOP in Newly Diagnosed PTCL

This is single-arm phase I/II study designed to evaluate the safety and efficacy of golcadotinib in combination with the CHOP regimen for patients with newly diagnosed peripheral T-cell lymphoma (PTCL). The study adopts a two-stage design, consisting of a Phase I and a Phase II parts. In the phase I study, a standard "3+3" design will be used. The primary endpoints of the Phase I study are the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D). The primary endpoint of the Phase II study is the complete response rate (CRR) of the golcadotinib combined with CHOP regimen.

Trial Details

NCT ID
NCT06739265
Phase
PHASE1 / PHASE2
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Golidocitinib plus CHOP
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Age between 18 and 70 years;
  • Histopathologically confirmed diagnosis of PTCL of one of the following subtypes: (1) Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS…
  • Patients must have at least one measurable lesion according to the Lugano 2014 criteria: For lymph node lesions, the measurable lymph node must hav…
  • ECOG performance status score of 0-3;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →